BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Arrowhead Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Arrowhead Pharmaceuticals's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06138743-10769@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SRP-1003: Phase 1/2 readout est. (NCT06138743)
DESCRIPTION:SRP-1003\, phase 1/2.\nStudy: Study of SRP-1003 in Participants
  With Type 1 Myotonic Dystrophy\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/srp-1003#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06138743
URL:https://assetmemo.bio/drug/srp-1003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937203-173@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ARO-ALK7: Phase 1/2 readout est. (NCT06937203)
DESCRIPTION:ARO-ALK7\, phase 1/2\, Obesity.\nStudy: A First-In-Human Study 
 of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellit
 us\nEstimated primary completion: February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/aro-alk7#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06937203
URL:https://assetmemo.bio/drug/aro-alk7#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06537414-10996@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Daplusiran/Tomligisiran: Phase 2 readout est. (NCT06537414)
DESCRIPTION:Daplusiran/Tomligisiran\, phase 2\, Chronic Hepatitis B.\nStudy
 : A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Fol
 lowed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB
 )\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/daplusiran-tomligisiran#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06537414
URL:https://assetmemo.bio/drug/daplusiran-tomligisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221344-694@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ARO-MAPT-SC: Phase 1/2 readout est. (NCT07221344)
DESCRIPTION:ARO-MAPT-SC\, phase 1/2\, Alzheimer's Disease.\nStudy: Trial of
  ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer
 's Disease or Primary Tauopathies\nEstimated primary completion: June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/aro-mapt-sc#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07221344
URL:https://assetmemo.bio/drug/aro-mapt-sc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223658-1090@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:ARO-DIMER-PA: Phase 1/2 readout est. (NCT07223658)
DESCRIPTION:ARO-DIMER-PA\, phase 1/2\, Mixed Hyperlipidemia.\nStudy: Study 
 of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia\nEstimated 
 primary completion: July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/aro-dimer-pa#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07223658
URL:https://assetmemo.bio/drug/aro-dimer-pa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037771-1192@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Zodasiran: Phase 3 readout est. (NCT07037771)
DESCRIPTION:Zodasiran\, phase 3\, Homozygous Familial Hypercholesterolemia.
 \nStudy: A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects Wit
 h Homozygous Familial Hypercholesterolemia (YOSEMITE)\nEstimated primary c
 ompletion: 20 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zodasiran#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07037771
URL:https://assetmemo.bio/drug/zodasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06700538-174@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:ARO-INHBE: Phase 1/2 readout est. (NCT06700538)
DESCRIPTION:ARO-INHBE\, phase 1/2\, Obesity.\nStudy: A First-In-Human Study
  of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mell
 itus\nEstimated primary completion: 15 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/aro-inhbe#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06700538
URL:https://assetmemo.bio/drug/aro-inhbe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06613698-6673@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Gatuzosiran: Phase 2 readout est. (NCT06613698)
DESCRIPTION:Gatuzosiran\, phase 2.\nStudy: A Study to Investigate the Safet
 y and Efficacy of GSK4532990 Compared With Placebo in Adult Participants A
 ged 18 to 70 Years With Alcohol-related Liver Disease\nEstimated primary c
 ompletion: 26 November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gatuzosiran#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06613698
URL:https://assetmemo.bio/drug/gatuzosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241546-3744@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ARO-RAGE: Phase 2 readout est. (NCT07241546)
DESCRIPTION:ARO-RAGE\, phase 2\, Asthma.\nStudy: Study of Inhaled ARO-RAGE 
 in Allergen-induced Mild Asthma\nEstimated primary completion: December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/aro-rage#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07241546
URL:https://assetmemo.bio/drug/aro-rage#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05581303-1039@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olpasiran: Phase 3 readout est. (NCT05581303)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduct
 ion (OCEAN(a)) - Outcomes Trial\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olpasiran#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05581303
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293260-1039@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Olpasiran: Phase 3 readout est. (NCT07293260)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduct
 ion - Coronary Computed Tomography Angiography Trial\nEstimated primary co
 mpletion: 15 June 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/olpasiran#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07293260
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822790-1043@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06822790)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Hypertriglyceridemia.\nStudy:
  Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglycer
 idemia\nEstimated primary completion: July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/plozasiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06822790
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07473843-1192@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Zodasiran: Phase 3 readout est. (NCT07473843)
DESCRIPTION:Zodasiran\, phase 3\, Homozygous Familial Hypercholesterolemia.
 \nStudy: Study of Zodasiran in Adolescent Participants With Homozygous Fam
 ilial Hypercholesterolemia\nEstimated primary completion: July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zodasiran#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07473843
URL:https://assetmemo.bio/drug/zodasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06165341-10767@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280826
DTEND;VALUE=DATE:20280827
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT06165341)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 Study to Learn About the Safety of Fazirsiran and if it Can Help People Wi
 th Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)\n
 Estimated primary completion: 26 August 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fazirsiran#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06165341
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06131983-10768@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SRP-1001: Phase 1/2 readout est. (NCT06131983)
DESCRIPTION:SRP-1001\, phase 1/2\, Facioscapulohumeral Muscular Dystrophy.\
 nStudy: Study of SRP-1001 in Adult and Adolescent Participants With Facios
 capulohumeral Muscular Dystrophy Type 1\nEstimated primary completion: 31 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/srp-10
 01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6131983
URL:https://assetmemo.bio/drug/srp-1001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05677971-10767@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20290117
DTEND;VALUE=DATE:20290118
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT05677971)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help P
 eople With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Versio
 n of Alpha-1 Antitrypsin Protein\nEstimated primary completion: 17 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fazirsiran#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0567797
 1
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880770-1043@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06880770)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: Study of Plozasiran in Adults With Severe Hypertriglyceridemia at 
 Risk of Acute Pancreatitis\nEstimated primary completion: March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/plozasiran#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06880770
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859813-174@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:ARO-INHBE: Phase 2 readout est. (NCT07859813)
DESCRIPTION:ARO-INHBE\, phase 2.\nStudy: A Trial to Evaluate the Efficacy a
 nd Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Ste
 atohepatitis\nEstimated primary completion: October 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/aro-inhbe#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07859813
URL:https://assetmemo.bio/drug/aro-inhbe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136012-1039@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20311020
DTEND;VALUE=DATE:20311021
SUMMARY:Olpasiran: Phase 3 readout est. (NCT07136012)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And L
 ipoprotein(a) Reduction to Prevent First Major Cardiovascular Events\nEsti
 mated primary completion: 20 October 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olpasiran#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07136012
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05899673-10767@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20330502
DTEND;VALUE=DATE:20330503
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT05899673)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 An Extension Study to Learn About the Long-Term Safety of Fazirsiran and i
 f Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease\nEstim
 ated primary completion: 2 May 2033. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fazirsiran#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05899673
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
